Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
9,155.00
+264.00 (2.97%)
At close: Dec 4, 2025
47.66%
Market Cap 105.71B
Revenue (ttm) 55.55B
Net Income (ttm) 2.36B
Shares Out n/a
EPS (ttm) 2.04
PE Ratio 44.78
Forward PE 10.83
Dividend n/a
Ex-Dividend Date n/a
Volume 1,493,772
Average Volume 1,372,652
Open 9,005.00
Previous Close 8,891.00
Day's Range 8,967.00 - 9,166.00
52-Week Range 4,865.00 - 9,166.00
Beta 0.70
RSI 78.37
Earnings Date Jan 28, 2026

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing af...

5 hours ago - 24/7 Wall street

Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News

Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News

1 day ago - GuruFocus

Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript

1 day ago - GuruFocus

Israel Has Been Mired In Controversy During Its War With Hamas. Big Tech Investment Tells A Different Story.

Israel's stock market has outpaced U.S. markets since Oct. 7, 2023, with U.S.-traded leaders like Teva, Elbit Systems and Tower Semiconductor showing big gains.

2 days ago - Investor's Business Daily

TEVA Forecasts Significant Rise in Cash Flow by 2030

TEVA Forecasts Significant Rise in Cash Flow by 2030

3 days ago - GuruFocus

Noteworthy ETF Inflows: IEFA, SPOT, SE, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an ap...

4 days ago - Nasdaq

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks

Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte...

6 days ago - The Motley Fool

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) short interest as a percent of float has risen 6.52% since its last report. According to exchange reported data, there are now 50.39 million shares s...

9 days ago - Benzinga

Teva: European Commission Grants Marketing Authorizations For Biosimilars PONLIMSI, DEGEVMA

(RTTNews) - Teva Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries (TEVA), announced that the European Commission has granted marketing authorizations for its two denosumab...

11 days ago - Nasdaq

Teva (TEVA) Gains European Approval for Denosumab Biosimilars

Teva (TEVA) Gains European Approval for Denosumab Biosimilars

11 days ago - GuruFocus

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European Comm...

11 days ago - GlobeNewsWire

This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.

Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA), Insmed (NASD...

12 days ago - 24/7 Wall street

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu...

14 days ago - Benzinga

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December

TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu...

14 days ago - GlobeNewsWire

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report

A federal jury has convicted Ruthia He, the founder of the telehealth startup Done Global, for orchestrating a scheme that transformed the company into an unrestricted source for Adderall prescription...

17 days ago - Benzinga

Teva (TEVA) Launches Innovative Platform to Drive Technological Advancement

Teva (TEVA) Launches Innovative Platform to Drive Technological Advancement

17 days ago - GuruFocus

Teva seeks startups to help solve global pharmaceutical challenges

Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceutical...

17 days ago - Reuters

Insider Sell: Christine Fox Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Insider Sell: Christine Fox Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

17 days ago - GuruFocus

Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)

Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)

21 days ago - GuruFocus

Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business

See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround. Click for more on TEVA and its earnings.

22 days ago - Seeking Alpha

Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock

A substantial insider sell was reported on November 10, by Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), based on the recent SEC filing. What Happened: A Form 4 fil...

25 days ago - Benzinga

Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023

Quarterly-filed Form 13Fs can clue investors into which stocks and trends are piquing the interest of Wall Street's brightest money managers. Billionaire Stanley Druckenmiller dumped his fund's holdin...

25 days ago - The Motley Fool

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today

Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently, Teva Pharmaceutical I...

25 days ago - Benzinga